Korea
Intelligence Brief

The largest pharmaceutical companies enter 2026 with two facts pressing on them at once: a patent cliff estimated to put roughly $170 billion of revenue at risk, and balance sheets carrying record cash. Industry analysts have noted that close to 40% of large-cap revenue faces loss of exclusivity within six years. With interest rates stabilizing and biotech valuations recovering off their 2025 lows, the result is a buying environment that several forecasters expect to rank among the largest on record — biopharma deal value potentially exceeding $250 billion, a level seen only once before, in 2019.

Where the money is going

The loudest battleground is metabolic disease. The race in obesity has moved past first-generation injectables toward oral small molecules, maintenance therapies, and adjacent indications such as MASH — with well over a hundred metabolic assets in development across dozens of companies, the field is deep enough to sustain a sustained acquisition contest. Oncology remains the deepest pool of all, with interest concentrating in multispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals. Immunology and inflammation, neurology, cardiometabolic disease, and long-acting infectious-disease prevention round out the priority list.

A buyer's market with few sellers

The constraint in this cycle is not capital. It is the supply of differentiated, de-risked assets — and there are not enough of them to satisfy the number of buyers who need to refill pipelines on a deadline. A second signal sits underneath the therapeutic-area map: acquirers increasingly prize companies whose discovery is AI- and machine-learning-enabled, because speed-to-asset has itself become a strategic asset. The buyers are not only purchasing molecules. They are purchasing the ability to make more of them, faster.

The funding environment tells a consistent story. Biopharma venture investment ran near $25 billion across roughly 413 deals in 2025, down from about $28 billion the prior year and far below the 2021 peak above $44 billion. The first quarter of 2026 extended the squeeze at the earliest stages: on the order of 50 seed and Series A rounds worth about $2.3 billion, putting first-time financings on pace for their weakest year since before the pandemic. The exit door has narrowed in parallel — more than a hundred biotech IPOs priced in 2021; fewer than ten did in 2025.

The mechanism behind the gap

Investors are prioritizing established data packages, de-risked development, and near-term catalysts. The practical consequence is that the hardest capital to raise in the entire market right now is a biotech Series B — the round that bridges a first financing to the larger one needed to generate Phase II data. This is the valley of death, and it has deepened. Strategic acquirers, meanwhile, tend to enter at positive Phase II/IIB data, the inflection point where development risk drops sharply. In the first quarter of 2026, large-cap takeovers stayed focused on later-stage programs even as upfront values climbed — roughly $40.9 billion committed versus about $28.7 billion a year earlier.

Why Korean assets stall at the bridge

Korean companies frequently arrive at this bridge with strong preclinical and early-clinical data. What they often lack is a U.S. clinical footprint, continuity of presence in front of U.S. investors, and the translation of their data into the language U.S. capital and regulators expect. The gap is not a failure of the science. It is a failure of the science to be seen, understood, and trusted at the moment capital decides where to concentrate.

In May 2025, the administration issued an executive order directing manufacturers to offer Americans a "most-favored-nation" price — benchmarked to the lowest price paid among developed nations, with the policy aimed at single-source brand-name drugs and biologics. The mechanism references prices in OECD countries whose GDP per capita is at least 60% of the United States'. Through 2025 and into 2026 the policy hardened: an April 2026 executive order tied tariff relief and other benefits to manufacturers willing to enter most-favored-nation and domestic-production agreements, with tariffs facing those who decline. By May 2026, the administration reported voluntary pricing agreements with seventeen of the world's largest manufacturers, and had publicly called for the policy to be written into law.

The sequencing trap

Reference pricing changes the arithmetic of a global launch. Under a most-favored-nation framework, the lowest price a drug accepts in any peer market can become the anchor for its U.S. price. That turns launch sequencing — the order in which a company enters markets, and the price it takes in each — into a decision with direct U.S. revenue consequences. A price set to win an early home-market approval can quietly cap the far larger U.S. opportunity. The companies that suffer most are the ones that treat pricing as a regulatory afterthought rather than a strategy set at the outset.

Why it cannot wait

The decisive choices are made before the first ex-U.S. price is set. Once a low reference price exists in a peer market, it is difficult to unwind. For a company that has not yet launched anywhere, the entire sequence is still a choice. For one that has, the constraint may already be inherited.

The change underway is in how molecules are made. Rather than screening existing libraries, generative models now design purpose-built molecules optimized for a target from the outset. In documented cases, teams have nominated a preclinical candidate after evaluating on the order of dozens of molecules rather than thousands — in roughly 18 months and at a fraction of the cost typically required. The market for AI-enabled drug discovery is estimated to have grown from about $5–7 billion in 2025 toward $8–10 billion in 2026.

The capital is already moving

The clearest signal is what the largest companies are buying. In early 2026, major pharmaceutical firms paid for access to discovery foundation models — one committing tens of millions upfront for an oncology model, another taking an annual access fee to a molecular-design platform. Speed-to-asset is now something even the biggest players choose to rent rather than build alone.

The honest caveat

As of early 2026, no fully AI-discovered drug has received final FDA approval. The Phase II and Phase III readouts due across 2026 and 2027 will either validate the decade-long investment thesis or force a recalibration; some observers note that AI-discovered compounds have so far progressed at rates similar to traditionally discovered ones. Regulation is moving in step — U.S. FDA guidance on AI is expected to be finalized in 2026, and the EU AI Act's high-risk provisions take effect in August 2026, potentially classifying some drug-development AI as high-risk. AI has changed the math of discovery. It has not yet changed the math of approval.

Where Korea holds an edge

Korea brings deep computational and chemistry talent, manufacturing discipline, and a substantial base of targets and compounds. The constraint is the same one that applies everywhere: translating platform speed into validated, investable, U.S.-legible assets.

I went to Miami in March to watch a market form. The BIO Investment & Growth Summit this year was, in effect, the opening of a buyer's market — a record dealmaking year taking shape around a thin shelf of assets, with capital visibly hunting for the few late-stage, differentiated, AI-enabled programs that could refill pipelines on deadline. The money was not cautious. It was looking.

And in that environment, Korea was absent from the room and present in nearly every conversation. I counted two Korean faces across two full days. Yet almost every investor I spoke with had a Korea story — a company they had once looked at, a molecule they had heard about, a partner they had lost track of. The interest was real. The presence was not.

The gap is structural, not scientific

That contradiction is the entire thesis of this brief. The capital is moving toward precisely what Korea produces — de-risked oncology and metabolic assets, AI-enabled discovery platforms, strong chemistry. The supply exists and the demand exists. They are simply not in the same room, and when they are not, the deal does not happen. The barrier is translation, continuity, and packaging — not the quality of the work.

The corridor is the answer to the room

A summit is one room for three days. What Korean innovation needs is the year-round version of that room: continuous presence, credible translation, and a known point of contact when an investor's Korea story is ready to become a Korea decision. That is the work. This brief is the first instrument of it.